1Q23 Business Results

Remsima® & Inflectra™M RemsimaⓇ, the most prescribed Infliximab drug in Europe, marked 10th anniversary after its first launch; M/S has risen by the dual formulation strategy with RemsimaⓇSC ✓ Inflectra™ has constantly grown in the US market after being listed as the preferred drug by major US payers Market share of RemsimaⓇ in Europe and Japan 57% 59% 57% 56% 55% 55% 54% 53% 53% 52% 52% 49% 26% 21% 21% 22% 19% 16% 12% 10% 8% 7% 6% 5% Market share of Inflectra™ in the US 12% 9% 6% '18 '19 17.3Q 18.1Q 3Q 19.1Q 3Q 20.1Q 3Q 21.1Q 3Q 22.1Q 3Q 4Q Note: market share is based on volume Source: IQVIA Europe Japan '20 23% 33% 32% '21 122 Inflectra™ ■■■A Biosimilar ■■■B Biosimilar Note: market share is based on volume Source: Symphony Health '23.1Q Investor Relations 2023 6 1Q23 Business Results Key Products Plan & Vision Appendix

View entire presentation